The effects of increased FKBP51 levels in the glucocorticoid treatment of Eosinophilic Esophagitis

Document Type


Publication Date



Biology | Life Sciences


Julie Caldwell and Marc Rothenberg, Cincinnati Children Hospital Medical Center; Michael Reagan and Charles Rodell, Biology


Eosinophilic Esophagitis (EE) is a recently discovered allergic disease that is characterized by an accumulation of eosinophils in the esophagus. In a previous clinical study, half of EE patients treated with the glucocorticoid drug Flovent responded to the treatment. Our study examined why Flovent worked for half of EE patients by creating a model system in esophageal epithelial cells. The results indicated that the gene FKBP51, which was highly expressed in patients who responded to the drug, was an important regulator of the drug's cellular pathway and high levels of FKBP51 can perhaps help predict whether a patient will respond to Flovent treatment.